Exome Asset Management’s Zenas BioPharma ZBIO Stock Holding History

Exome Asset Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.58M	Buy	+80,730	New	+$1.81M	0.82%	42

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Exome Asset Management's ZBIO Position: Q1 2026 in Review

Exome Asset Management opened a new position in Zenas BioPharma (ZBIO) in Q1 2026: 80,730 shares worth $1.58M. The stake represents 0.82% of the portfolio and ranks #42 among its holdings.

139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

Exome Asset Management held 80,730 shares of Zenas BioPharma worth $1.58M as of Q1 2026.
Zenas BioPharma was a new Exome Asset Management position in Q1 2026.
Zenas BioPharma made up 0.82% of Exome Asset Management's portfolio in Q1 2026, its #42 holding.
139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.